Published in Cancer on August 15, 2010
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis | NCT02399410
Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol (2011) 4.56
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg (2013) 2.12
Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model. J Surg Oncol (2013) 1.52
Peritoneal carcinomatosis. World J Gastroenterol (2013) 1.04
Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol (2014) 1.00
Prevention of Peritoneal Metastases from Colon Cancer in High-Risk Patients: Preliminary Results of Surgery plus Prophylactic HIPEC. Gastroenterol Res Pract (2012) 0.98
Colorectal cancer: Metastases to a single organ. World J Gastroenterol (2015) 0.97
Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg (2012) 0.96
Colorectal cancer: prevention and management of metastatic disease. Biomed Res Int (2014) 0.93
Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int (2011) 0.92
Prognostic factors for peritoneal carcinomatosis originating from colorectal cancer: an analysis of 921 patients from a multi-institutional database. Surg Today (2014) 0.92
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer: 2-year follow-up results at a single institution in Korea. Ann Surg Treat Res (2016) 0.89
Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer (2014) 0.89
Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases. World J Gastroenterol (2014) 0.87
Management of peritoneal carcinomatosis from colorectal cancer: review of the literature. Int J Colorectal Dis (2014) 0.85
Oxaliplatin and molecular-targeted drug therapies improved the overall survival in colorectal cancer patients with synchronous peritoneal carcinomatosis undergoing incomplete cytoreductive surgery. Surg Today (2014) 0.84
Peritoneal Carcinomatosis from Colon Cancer: A Systematic Review of the Data for Cytoreduction and Intraperitoneal Chemotherapy. Clin Colon Rectal Surg (2015) 0.82
Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. PLoS One (2015) 0.82
Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future. J Gastrointest Oncol (2016) 0.82
Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol (2014) 0.82
Morbidity and mortality of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: national cancer institute, Mexico city, Mexico. ISRN Oncol (2011) 0.81
Cytoreductive surgery plus hyperthermic perioperative chemotherapy for selected patients with peritoneal metastases from colorectal cancer: a new standard of care or an experimental approach? Gastroenterol Res Pract (2012) 0.81
Preclinical antitumor activity of a nanoparticulate SN38. Invest New Drugs (2013) 0.79
Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. Surg Today (2014) 0.79
Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol (2016) 0.79
Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis. J Gastroenterol (2015) 0.79
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol (2016) 0.78
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer and other less common disease histologies: is it time? J Gastrointest Oncol (2016) 0.78
Abdominal metastases from colorectal cancer: intraperitoneal therapy. J Gastrointest Oncol (2015) 0.77
Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol (2016) 0.77
Peritoneal metastases of colorectal origin treated by cytoreduction and HIPEC: An overview. World J Gastrointest Oncol (2014) 0.77
Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer. Oncol Lett (2016) 0.77
Prognostic Relevance of the Peritoneal Surface Disease Severity Score Compared to the Peritoneal Cancer Index for Colorectal Peritoneal Carcinomatosis. Int J Surg Oncol (2016) 0.76
Surgical treatment of peritoneal carcinomatosis: current treatment modalities. Langenbecks Arch Surg (2013) 0.76
Laparoscopic cytoreductive surgery and early postoperative intraperitoneal chemotherapy for patients with colorectal cancer peritoneal carcinomatosis: initial results from a single center. Surg Endosc (2013) 0.76
Peritoneal carcinomatosis of gastrointestinal tumors: where are we now? World J Gastroenterol (2014) 0.76
Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol (2016) 0.75
Clinical practice guidelines for the management of metastatic colorectal cancer: a consensus statement of the Hellenic Society of Medical Oncologists (HeSMO). Ann Gastroenterol (2016) 0.75
"En bloc" caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancer. World J Gastroenterol (2016) 0.75
Short-term outcome in patients treated with cytoreduction and HIPEC compared to conventional colon cancer surgery. Medicine (Baltimore) (2016) 0.75
Multidisciplinary Treatment for Colorectal Peritoneal Metastases: Review of the Literature. Gastroenterol Res Pract (2016) 0.75
Gastric perforation following cytoreductive surgery and perioperative intraperitoneal chemotherapy: a case series of six. World J Surg Oncol (2017) 0.75
Extravascular use of drug-eluting beads: a promising approach in compartment-based tumor therapy. World J Gastroenterol (2013) 0.75
Localized peritoneal carcinomatosis mimicking an irreducible left inguinal hernia. Ann R Coll Surg Engl (2016) 0.75
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget (2017) 0.75
Preoperative platelet-lymphocyte ratio is an independent prognostic marker and superior to carcinoembryonic antigen in colorectal peritoneal carcinomatosis patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Int J Clin Oncol (2017) 0.75
Prognoses and treatment strategies for synchronous peritoneal dissemination of colorectal carcinoma. Surg Today (2015) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Endogenous HMGB1 regulates autophagy. J Cell Biol (2010) 4.71
Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg (2013) 3.94
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
High-mobility group box 1 and cancer. Biochim Biophys Acta (2010) 3.11
Robotic versus laparoscopic hepatectomy: a matched comparison. Ann Surg (2014) 2.58
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
Meckel's diverticulum--a high-risk region for malignancy in the ileum. Insights from a population-based epidemiological study and implications in surgical management. Ann Surg (2011) 2.56
Masquerader: high mobility group box-1 and cancer. Clin Cancer Res (2007) 2.40
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest (2007) 2.36
PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev (2012) 2.24
High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal (2011) 2.19
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res (2011) 1.98
High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab (2011) 1.89
Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1.82
Robotic-assisted major pancreatic resection and reconstruction. Arch Surg (2010) 1.82
Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs (2009) 1.79
HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 1.79
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Arginine and immunity. J Nutr (2007) 1.62
Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics (2005) 1.56
Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol (2008) 1.52
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol (2010) 1.48
Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol (2010) 1.47
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res (2012) 1.46
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res (2012) 1.41
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc (2010) 1.30
HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy (2010) 1.30
The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A (2012) 1.30
High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal (2011) 1.27
Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 1.26
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol (2013) 1.24
250 robotic pancreatic resections: safety and feasibility. Ann Surg (2013) 1.23
Hepatic abscess in patients with chronic granulomatous disease. Ann Surg (2002) 1.22
Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol (2007) 1.21
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
Real-time three-dimensional Fourier-domain optical coherence tomography video image guided microsurgeries. J Biomed Opt (2012) 1.21
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res (2012) 1.17
C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst (2011) 1.16
Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol (2006) 1.14
Diagnosis and management of retroperitoneal ancient schwannomas. World J Surg Oncol (2009) 1.14
Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol (2013) 1.12
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol (2012) 1.12
Indications and approach to surgical resection of lung metastases. J Surg Oncol (2010) 1.11
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11
The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther (2005) 1.10
A reduction in delayed gastric emptying by classic pancreaticoduodenectomy with an antecolic gastrojejunal anastomosis and a retrogastric omental patch. J Gastrointest Surg (2009) 1.10
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery (2013) 1.09
Survival outcomes of patients with colorectal liver metastases following hepatic resection or ablation in the era of effective chemotherapy. Ann Surg Oncol (2008) 1.08
HMGB1 as an autophagy sensor in oxidative stress. Autophagy (2011) 1.08
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol (2006) 1.07
Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg (2002) 1.07
The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal (2011) 1.05
Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med (2008) 1.05
c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal (2010) 1.05
Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol (2009) 1.04
Ionizing radiation potentiates the antitumor efficacy of oncolytic herpes simplex virus G207 by upregulating ribonucleotide reductase. Surgery (2002) 1.04
The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol (2012) 1.03
Robotic-assisted major pancreatic resection. Adv Surg (2011) 1.03
DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy (2013) 1.02
Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation (2006) 1.02
Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res (2003) 1.01
Antibodies directed to pig non-Gal antigens in naïve and sensitized baboons. Xenotransplantation (2006) 1.01
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol (2009) 1.01
Ex situ resection techniques and liver autotransplantation: last resource for otherwise unresectable malignancy. Dig Dis Sci (2005) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy (2010) 1.00
A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol (2008) 1.00
Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA Surg (2013) 0.99
Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol (2014) 0.99